William Blair Analysts Decrease Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at William Blair dropped their Q1 2025 earnings per share estimates for shares of Axsome Therapeutics in a research note issued on Tuesday, April 1st. William Blair analyst M. Minter now forecasts that the company will post earnings of ($1.49) per share for the quarter, down from their previous estimate of ($1.46). William Blair has a “Outperform” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.31) EPS, Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($4.36) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at $0.47 EPS, Q4 2026 earnings at $1.13 EPS, FY2026 earnings at $1.10 EPS, FY2027 earnings at $12.30 EPS, FY2028 earnings at $25.02 EPS and FY2029 earnings at $38.11 EPS.

Several other research firms have also recently commented on AXSM. Wells Fargo & Company boosted their price target on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Robert W. Baird upped their target price on Axsome Therapeutics from $132.00 to $160.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a “buy” rating and a $176.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $153.00 price target on shares of Axsome Therapeutics in a report on Wednesday, February 19th. Finally, HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Axsome Therapeutics in a report on Thursday. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $167.64.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $98.86 on Friday. The company’s fifty day moving average price is $120.62 and its two-hundred day moving average price is $101.67. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The firm has a market capitalization of $4.82 billion, a P/E ratio of -16.50 and a beta of 0.88. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million for the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently added to or reduced their stakes in AXSM. JPMorgan Chase & Co. boosted its holdings in shares of Axsome Therapeutics by 14.9% during the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock valued at $19,062,000 after acquiring an additional 27,534 shares during the period. Strategic Financial Concepts LLC bought a new position in Axsome Therapeutics in the 4th quarter worth approximately $2,599,000. Intech Investment Management LLC raised its stake in Axsome Therapeutics by 46.5% during the 4th quarter. Intech Investment Management LLC now owns 16,028 shares of the company’s stock valued at $1,356,000 after acquiring an additional 5,087 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Axsome Therapeutics during the 4th quarter worth $14,771,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Axsome Therapeutics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company’s stock worth $27,755,000 after purchasing an additional 5,438 shares in the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.